Collection and analysis of adverse drug reactions of antiretroviral therapy in a tertiary care hospital in central India
Keywords:Adverse drug reaction, Antiretroviral therapy, AIDS, HIV, WHO
Background: The main objective of study is to monitor and analyze the adverse drug reactions (ADRs) of ART and to assess causality and severity of the ADRs detected.
Methods: It is a prospective observational study conducted in the ART centre of a tertiary care teaching hospital in central India. The data collected were recorded on standard ADR reporting forms. Causality was assessed by Naranjo’s algorithm. Severity of ADR’s was assessed by modified Hartwig and Seigel scale. Modified Shumock and Thorton criteria used for preventability assessment.
Results: In twelve months duration 351 patients on ART were observed for ADRs. Total 166 ADRs detected in 96 patients. Incidence of ADRs was slightly more in female. The common systems involved were gastrointestinal 42.77% followed by nervous system 18.07%, musculoskeletal 15.06% skin/mucous membrane 07.83%, metabolic and nutritional 04.82%, red blood cell disorders 01.20 %, endocrinal 00.60 % and others 09.64%. The causality assessment as per Naranjo’s scale showed that out of 166 ADRs, 28.92% were probable and 71.08% were possible. Severity assessment by modified Hartwig and Siegel scale showed that 83.34% ADRs were mild and 15.66% were moderate. 46.39 % ADRs were probably preventable.
Conclusions: Considering the magnitude of ADR related problems, there is a need for greater awareness among health care professionals, to detect and report them. These ADRs if recognized in time and managed properly can prevent treatment interruption.
Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. AIDS Cohort Study Investigators. JAMA. 1998;280:1497-503.
Hogg RS, Yip B, Kully C, Craib KJP, O’Shaughnessy MV, Schechter MT. Improved survival among HIV-infected patients after initiation of triple drug antiretroviral regimens. CMAJ. 1999;160(5):659-65.
Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS. 2000;14:499-507.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-7.
HIV AND AIDS IN INDIA. Available at: http://www.avert.org/professionals/hiv-around-world/asia-pacific/india
Suspected adverse drug reaction reporting form- cdsco. Available at: cdsco.nic.in/writereaddata/ADRRF.pdf
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm.1992;27:538.
Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009 Jan;13(1):e1-8.
Rajesh R, Vidyasagar S, Nandakumar K. Highly active antiretroviral therapy induced adverse drug reactions in Indian human immunodeficiency virus positive patients. Pharmacy Practice (Internet). 2011;9(1):48-55.
Reddy AVK, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A Study on Adverse Drug Reactions In HIV Infected Patients At a ART Centre Of Tertiary Care Hospital In Guwahati, India. Asian J Pharm Clin Res. 2013;6(2):102-4.
Modayil RR, Harugeri A, Parthasarathi G, Ramesh M, Prasad R, Naik V, et al. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiology and drug safety. 2010;19(3):247-55.
Luma HN, Marie-Solange D, Simeon-Pierre C, Elvis T, Gloria A, Achu Joko H, et al. Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. P an African Medical Journal - ISSN: 1937- 8688.
WHO/Forum for collaborative HIV Research Joint Meeting, ARV drugs adverse events, case definition, grading, laboratory diagnosis and treatment monitoring, February 28-29, 2008. Geneva, Switzerland. Available at: http://www.hivforum.org/index.php? option=com_contentandtask=viewandid=59andItemid=102. Accessed on 16/10/2011.
Menezes de Pádua CA, César CC, Bonolo PF, Acurcio FA, Guimarães MDC. Self-Reported Adverse Reactions Among Patients Initiating Antiretroviral Therapy in Brazil. The Brazilian J of Inf Dise. 2007;11(1):20-6.
Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf. 2009;18(9):848-57.
Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases. 2000;30(2):96-116.
Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, et al. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: A sub study from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007;8:337-44.
Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J of Cli Vir. 2003 Feb 1;26(2):195-207.
Carr A, Cooper DA. Adverse Effects Of Antiretroviral Therapy. The Lancet. 2000;356(9239):1412-3.
Valentina M. Adverse effect of antiretroviral therapy for HIV infection Am Intern Medicine. 1987;107:35.
McLeod GX, Hammer SM. Zidovudine: 5 Years Later. Ann Intern Med. 1992;117:487-50.
Von Giesen HJ, Hefter H, Jablonowski H, Arendt G. Stavudine and the peripheral nerve in HIV-1 infected patients. J Neurol. 1999;246:211.
Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. The Lancet. 2001;357(9256):592-8.
Manfredi R, Calza L, Chiodo F. Gynaecomastia associated with highly active antiretroviral therapy. Annals of Pharmacotherapy. 2001;35:438-9.
Paech J, Lorenzen T, von Krosigk A, Graefe K, Stoehr A, Plettenberg A. Gynaecomastia in HIV-infected men: association with effects of antiretroviral therapy. AIDS. 2002;16:1193-4.
Piroth L, Grappin M, Petit JM, Buisson M, Duong M, Chavanet P, et al. Incidence of gynaecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis. 2001;3:559-60.
A practical handbook on the pharmacovigilance of antiretroviral medicines. WHO; 2013:44.
Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medicalin patients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008;65(3):396-406.